Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
37 results about "Neuroblastic Tumor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A group of nervous system tumors which display neuronal differentiation. It includes tumors that are composed of immature round cells and tumors that display advanced differentiation and the formation of ganglion cells.
Compounds as rearranged during transfection (RET) inhibitors
This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and / or secretion and / or abdominal disorders or diseases and / or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Use of phosphatases to treat neuroblastomas and medulloblastomas
InactiveUS20090035292A1Effective treatmentBiocideHeavy metal active ingredientsHistone deacetylaseMedicine
Disclosed herein are methods of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a phosphatase ligand in an amount effective to treat the subject. Also disclosed herein are method of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a histone deacteylase ligand in an amount effective to treat the subject.
Owner:LIXTE BIOTECH +1
Natural and synthetic isothiocyanate kind compound and its application in treating and preventing cancer
The invention relates to naturally or artificially synthesized iso-thiocyanates i.e. JC-5411 compounds and their use in treating and preventing malignant tumor, wherein the compounds can directly suppress the methylation of the gene promoter / 5-UTR area CpG DNA, directly inhibit the reactivity of histone deacethylases (HADC), selectively promote histone acetylation and methylation, then further recover the expression of genes with important functions that are shut abnormally in cancer cells, thus control the malignant proliferation of cancer cells.
Owner:JC (WUXI) CO INC
Diagnosis and treatment of neuroectodermal tumors
The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.
Owner:TRANSMOLECULAR INC
Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors
InactiveUS9072778B2Effective treatmentTreatment safetyBiocideHydroxy compound active ingredientsDiseaseDietary supplement
The present invention relates to methods and compositions for treating diseases. More specifically, the present invention relates to the administration of multiple drugs as part of a treatment of disease. Specific embodiments of the invention relate to a treatment regimen for neuroblastomas and other N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors, comprising administering multiple therapeutic compounds like DFMO, SAM486A, a verinoid and a cytotoxic drug and placing the patient on a low polyamine diet and / or providing the patient with a polyamine limiting dietary supplement.
Owner:UNIV OF HAWAII +1
Diagnosis and treatment of neuroectodermal tumors
InactiveUS20100215576A1Peptide/protein ingredientsRadioactive preparation carriersMelanomaSmall-cell carcinoma
Owner:UAB RES FOUND
Specific indole compound and its preparation and use in treating and preventing cancers
InactiveCN1424312APrevent proliferationInduce apoptosisOrganic active ingredientsNervous disorderOrganic synthesisMedicine
An organic heterocycle compound series JN-2158 is prepared by organic synthetic reaction. It can be used in medicine field to treat more diseases of people and animal, such as cancers, senitile dementia, psoriasis, cardiovascular diseas, glomerulonephritis, etc and prevent and cure AIDS.
Owner:JC (WUXI) CO INC
Methods and Compositions for Treating Neuroblastoma
InactiveUS20110206691A1Organic active ingredientsMicrobiological testing/measurementCancer researchNeuroblastic Tumor
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
Compounds for cancer imaging and therapy
InactiveUS20010006619A1BiocideGroup 3/13 element organic compoundsAbnormal tissue growthPheochromocytoma
The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.
Owner:RES CORP TECH INC
Methods and compounds for treating cancer
The invention includes, in part, methods and compounds for treating cancer including, but not limited to gliomas, melanomas, and neuroblastomas. In some embodiments of the invention, a glyceryltriacetate compound is administered to a subject in an amount effective to treat or prevent a cancer in the subject.
Owner:UNIVERSITY OF VERMONT
GD2 ligands
The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as cancers in which cells express GD2, including neuroblastomas.
Owner:MCGILL UNIV
Compositions and their use as anti-tumor agents
The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreating carcinomas) and mesotheliomas.
Owner:COMPASS PHARMA
Use of propofol succinic acid monoester sodium salt in preparing anti-tumor medicine
The invention relates to an application of a propofol derivate, namely propofol succinic acid monoester sodium salt (I) in preparing anti-tumor drugs, in particular, the application thereof in preparing drugs for resisting breast cancer, liver cancer or neuroblastoma.
Owner:重庆医科大学医药研究所
Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
InactiveUS20090203784A1Effective treatmentTreatment safetyBiocideHydroxy compound active ingredientsDiseaseDietary supplement
The present invention relates to methods and compositions for treating diseases. More specifically, the present invention relates to the administration of multiple drugs as part of a treatment of disease. Specific embodiments of the invention relate to a treatment regimen for neuroblastomas and other N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors, comprising administering multiple therapeutic compounds like DFMO, SAM486A, a verinoid and a cytotoxic drug and placing the patient on a low polyamine diet and / or providing the patient with a polyamine limiting dietary supplement.
Owner:UNIV OF HAWAII +1
Preparation method of metaiodobenzylguanidine (MIBG) sulphate
InactiveCN104496856ALow skill level requiredImprove securityOrganic chemistryOrganic compound preparationPheochromocytomaNeuroblastic Tumor
The invention relates to the technical field of radiopharmaceuticals and in particular relates to a preparation method of a radiopharmaceutical *I-metaidobenzylguanidine labelled precursor metaiodobenzylguaidine sulphate applied in the aspects of treatment and diagnosis of neuroendocrine carcinoma including human pheochromocytoma, neuroblastoma and the like. By applying the provided preparation method of MIBG sulphate, MIBG sulphate purity reaches up more than 95%, a technology is simple and optimized compared with the existing MIBG sulphate preparation method, and economic cost is greatly reduced, so that the provided preparation method of MIBG sulphate is applicable to industrial large-scale production application.
Owner:BEIJING ZHIBO BIO MEDICAL TECH +1
Use of multiple target nucleic acid detection method using clamping probe and detection probe
PendingCN106536758AGrowth inhibitionEfficient detectionMicrobiological testing/measurementWild typeNon invasive
Owner:PANAGENE INC
Preparation method of anti-human Nogo-66 receptor protein vaccine and application thereof
InactiveCN101288771APromote regenerationPromote functional recoveryNervous disorderAntibody ingredientsEscherichia coliEukaryotic plasmids
The invention provides a method for preparing antihuman Nogo-66 receptor protein vaccine. An hNgR gene in full size is obtained by the PCR amplification from human neurobalstoma (SK-N-SH) cDNA. The amplified segment is inserted in a cloning vector and is sub-cloned to an expression vector pET28a (+) containing six His labels to obtain a recombinant expression plasmid pET28a-NgR. The recombinant plasmid is transformed into a coli expression strain BL21 (DE3) for the induced expression to obtain hNgR protein. By closing the effect of NgR and blocking the effect of inhibitory factor, the NgR protein vaccine can promote the regeneration of neurons axon after the spinal cord injury, can reduce the tissue necrosis in a damage zone, can promote the functional recovery of the injured spinal cord and express that the NgR protein vaccine is provided with a potential value for treating the spinal cord injury. The defect that exogenous biological agent can be easily eliminated by an autoimmune system is avoided. In addition, the characters that the cellular immunity is mainly induced after the DNA vaccination of NgR and only few individuals can induce humoral immunity are overcome.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Diaryl ethyl diether compound and pharmaceutically acceptable hydrate or salt as well as synthetic method and anti-tumor application thereof
InactiveCN108373469ANovel structureNSCLCOrganic chemistryAntineoplastic agentsPositive controlTert-Butyloxycarbonyl protecting group
The invention provides a diaryl ethyl diether compound and a pharmaceutically acceptable hydrate or salt as well as a synthetic method and anti-tumor application thereof. A structural general formulais as shown in the description. A preparation method comprises the following steps: dissolving 3-hydroxy-2 nitropyridine into DMF, adding 1,2-dibromoethane and potassium carbonate, and carrying out reaction, so that a compound e is obtained; dissolving the compound e into a solvent DMF, then adding a substance (as shown in the description) and potassium carbonate, then heating, and carrying out reaction, so that a compound d is obtained; reducing the compound d by virtue of iron powder, so that a compound c is obtained; dissolving the compound c into acetonitrile solution, and carrying out bromination reaction, so that a product b is obtained; adding the compound b and 1-(1-t-butyloxycarboryl piperidine-4-yl) pyrazole-4-boronic acid pinacol ester into DME, then adding Pd(dppf)Cl2 and Cs2CO3 aqueous solution, and carrying out reaction, so that a compound a is obtained; and adding the compound a into dichloromethane, dropwise adding 1,4-dioxane solution of hydrogen chloride under ice-bath condition, and carrying out reaction, so that the product is obtained. The compound provided by the invention is novel in structure, has the effect of resisting to non-small cell lung cancer and neuroblastoma and has the antitumor activity equivalent to or better than that of a positive control crizotinib.
Owner:DALIAN UNIV OF TECH
Applications of calcium-and inte-grin-binding protein 1 in preventing and treating enterovirus 71 infection
The invention belongs to the technical field of biomedicine, and relates to a novel target used for preventing enterovirus 71 infection, and applications thereof. According to the invention, SH-SY5Y is taken as the target cell, and RNA interference technology is adopted for down-regulation of expression of target cell host protein so as to search host factors capable of inhibiting EV71 infection of SH-SY5Y cells effectively and protect the functions of central nervous systems. It is fond by experiments that calcium-and inte-grin-binding protein, CIB1 molecular possesses significant importance in EV71 infection of SH-SY5Y, and down-regulation of expression of CIB1 is capable of inhibiting EV71 infection obviously. The invention also provides applications of CIB1 in preparing drugs used for preventing or treating EV71 infection.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Protopanaxadiol derivative and application thereof
ActiveCN103387596AHas inhibitory effectOrganic active ingredientsMicroorganism based processesProtopanaxadiolHepatic Cancers
The invention discloses a protopanaxadiol derivative and pharmaceutically-acceptable salts, esters or solvates thereof. The protopanaxadiol derivative and the pharmaceutically-acceptable salts, esters or solvates thereof have a structure shown in the formula I. The invention further discloses application of the protopanaxadiol derivative and the pharmaceutically-acceptable salts, esters or solvates thereof in the preparation of drugs for treating and / or preventing tumors, particularly cervical carcinoma, leukemia, neuroblastoma, prostatic carcinoma, liver cancer and mammary cancer.
Owner:南通药享科技有限公司
Biamido heterocyclic derivative with antitumour activity and its preparation method and use
A biamidoheterocyclic derivative with antineoplastic activity and its preparing process are disclosed. It can be used to treat cancers, such as chronic granulocyte leukemia, acute lymphocyte leukemia and melanotic cancer etc.
Owner:INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
Natural and synthetic isothiocyanate kind compound and its application in treating and preventing cancer
The invention relates to naturally or artificially synthesized iso-thiocyanates i.e. JC-5411 compounds and their use in treating and preventing malignant tumor, wherein the compounds can directly suppress the methylation of the gene promoter / 5-UTR area CpG DNA, directly inhibit the reactivity of histone deacethylases (HADC), selectively promote histone acetylation and methylation, then further recover the expression of genes with important functions that are shut abnormally in cancer cells, thus control the malignant proliferation of cancer cells.
Owner:JC (WUXI) CO INC
Application of dynamin 1 in prevention and treatment on enterovirus type 71 infection
ActiveCN105497918AAvoid infectionDoes not affect physiological functionOrganic active ingredientsGenetic material ingredientsNervous systemNeuroblastic Tumor
The invention relates to the technical field of biomedicine, and provides a new target for resisting entervirus type 71 infection and application. A human neuroblastoma cell (SH-SY5Y) is taken as a target cell, expression of host protein of the target cell is down-regulated by adopting an RNA interference technique to look for a host factor which can effectively inhibit the EV71-infected human neuroblastoma cell (SH-SY5Y), and therefore the function of a central nervous system is protected. Through experiments, it is found that a dynamin 1 (NDM1) plays an important role on the EV71-infected SH-SY5Y, and EV71 infection can be obviously inhibited by down-regulating expression of the DNM1. The invention provides application of the DNM1 in preparation of medicine for preventing or treating the entervirus type 71 infection.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Three-level cyclic amine ALK kinase inhibitor used for treating cancer
ActiveCN104059054ALow brightnessEnhanced inhibitory effectOrganic active ingredientsOrganic chemistryDiseaseThree level
Provided are substituted cyclic amine compounds, and pharmaceutically acceptable salts and pharmaceutical preparations thereof as an anaplastic lymphoma kinase (ALK) inhibitor. Also provided is the use of the compound and pharmaceutical preparations thereof in the preparation of drugs for the treatment and inhibition of diseases including non-small cell lung cancer (NSCLC), neuroblastomas, anaplastic large cell lymphoma (ALCL), liver cancer and other diseases caused by the rise of the ALK activity level.
Owner:ZHEJIANG DTRM BIOPHARMA
Cinacalcet and neuroblastic tumours
The present invention relates to the field of pediatric or childhood tumor therapy. More specifically, the invention relates to the use of the allosteric activator of the calcium sensor receptor, cinacalcet, for the preparation of a pharmaceutical product for the treatment of neuroblastic tumors, particularly for the treatment of neuroblastomas, ganglioneuroblastomas and ganglioneuromas.
Owner:HOSPITAL SANT JOAN DE DEU +1
Bi-amido heterocyclic derivative with antitumour activity and its preparation method and use
A biamidoheterocyclic derivative with antineoplastic activity and its preparing process are disclosed. It can be used to treat cancers, such as chronic granulocyte leukemia, acute lymphocyte leukemia and melanotic cancer etc.
Owner:INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
Method for genetically modifying and inducing intracerebral transplantation mesenchymal stem cells to be differentitated into neuron
InactiveCN100408677CMaintain multiple differentiation potentialStable expressionNervous disorderGenetic material ingredientsAbnormal tissue growthCDNA library
The present invention is aimed at providing a method for utilizing external gene operation to induce the intracerebral transplanted mesenchymal stem cell to implement directed differentiation and make it into neurone. Its technical scheme includes the following steps: (1). using self-body biological characteristics to separate, amplify the purify mesenchymal stem cell; (2). cloning brain-derived neurotrophic factor cDNA sequence from human neuroblast tumor cDNA library, constructing retroviral vector of recombinant human brain-derived neurotrophic factor gene and introducing the brain-derived neutrotrophic factor gene into mesenchymal stem cell; and (3). utilizing cerebral stereo-orientation method to make the mesenchymal stem cell modified by brain-derived neurotrophic factor gene be transplanted into brain. Under the induction of neurotrophic factor the ratio of defferentiating mesenchymal stem cell into neurone can be obviously raised. Said invention also provides its application value.
Owner:FIELD OPERATION BLOOD TRANSFUSION INST OF PLA SCI ACAD OF MILITARY +1
A kind of diaryl ethylene ether compound and its pharmaceutically acceptable salt, synthetic method
InactiveCN108373469BNovel structureGood antitumor activityOrganic chemistryAntineoplastic agentsPositive controlTert-Butyloxycarbonyl protecting group
The invention provides a diaryl ethyl diether compound and a pharmaceutically acceptable hydrate or salt as well as a synthetic method and anti-tumor application thereof. A structural general formulais as shown in the description. A preparation method comprises the following steps: dissolving 3-hydroxy-2 nitropyridine into DMF, adding 1,2-dibromoethane and potassium carbonate, and carrying out reaction, so that a compound e is obtained; dissolving the compound e into a solvent DMF, then adding a substance (as shown in the description) and potassium carbonate, then heating, and carrying out reaction, so that a compound d is obtained; reducing the compound d by virtue of iron powder, so that a compound c is obtained; dissolving the compound c into acetonitrile solution, and carrying out bromination reaction, so that a product b is obtained; adding the compound b and 1-(1-t-butyloxycarboryl piperidine-4-yl) pyrazole-4-boronic acid pinacol ester into DME, then adding Pd(dppf)Cl2 and Cs2CO3 aqueous solution, and carrying out reaction, so that a compound a is obtained; and adding the compound a into dichloromethane, dropwise adding 1,4-dioxane solution of hydrogen chloride under ice-bath condition, and carrying out reaction, so that the product is obtained. The compound provided by the invention is novel in structure, has the effect of resisting to non-small cell lung cancer and neuroblastoma and has the antitumor activity equivalent to or better than that of a positive control crizotinib.
Owner:DALIAN UNIV OF TECH
Traditional Chinese medicine extract for resisting neuroblastoma as well as preparation process and application of traditional Chinese medicine extract
InactiveCN104586950APrevent proliferationWide variety of sourcesAntineoplastic agentsPlant ingredientsAcetic acidMedicine
The invention discloses a traditional Chinese medicine extract for resisting neuroblastoma as well as a preparation process and an application of the traditional Chinese medicine extract. The traditional Chinese medicine extract, which is an extract of osmanthus fragrans lour, is obtained by extracting pressed and deoiled osmanthus fragrans lour cake by virtue of water and ethyl acetate sequentially. The traditional Chinese medicine extract disclosed by the invention, which is prepared from a single Chinese herbal medicine, is not only capable of inhibiting the proliferation of human bone marrow neuroblastoma cells, but also wide in raw material source; therefore, the traditional Chinese medicine extract is low in production cost, and is of great social and economic significance.
Owner:李健
Application of calcium integrin binding protein 1 in preventing and treating enterovirus 71 infection
The invention belongs to the technical field of biomedicine, and relates to a novel target used for preventing enterovirus 71 infection, and applications thereof. According to the invention, SH-SY5Y is taken as the target cell, and RNA interference technology is adopted for down-regulation of expression of target cell host protein so as to search host factors capable of inhibiting EV71 infection of SH-SY5Y cells effectively and protect the functions of central nervous systems. It is fond by experiments that calcium-and inte-grin-binding protein, CIB1 molecular possesses significant importance in EV71 infection of SH-SY5Y, and down-regulation of expression of CIB1 is capable of inhibiting EV71 infection obviously. The invention also provides applications of CIB1 in preparing drugs used for preventing or treating EV71 infection.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com